ReviewChemMedChem2021
Preparing (Metalla)carboranes for Nanomedicine.
Review in ChemMedChem, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Review
- Development of Carborane-Based Halogenated Naphthyridinone-Analogues as Cannabinoid Receptor Type 2 (CBChemMedChem · 2025Article
- Carborane Conjugates with Ibuprofen, Fenoprofen and Flurbiprofen: Synthesis, Characterization, COX Inhibition Potential and In Vitro Activity.ChemMedChem · 2025Article
- Review
- Chemistry of Carbon-Substituted Derivatives of Cobalt Bis(dicarbollide)(1Molecules (Basel, Switzerland) · 2023Review
- Towards the Application of Purely Inorganic Icosahedral Boron Clusters in Emerging Nanomedicine.Molecules (Basel, Switzerland) · 2023Review
- Metallacarborane Synthons for Molecular Construction-Oligofunctionalization of Cobalt Bis(1,2-dicarbollide) on Boron and Carbon Atoms with Extendable Ligands.Molecules (Basel, Switzerland) · 2023Article
- Synthesis and Structural Characterization ofMolecules (Basel, Switzerland) · 2023Article
- Development of the High-Affinity Carborane-Based Cannabinoid Receptor Type 2 PET Ligand [Journal of medicinal chemistry · 2023Article
- Biosynthesized Gold, Silver, Palladium, Platinum, Copper, and Other Transition Metal Nanoparticles.Pharmaceutics · 2022Review
- Carboranes as unique pharmacophores in antitumor medicinal chemistry.Molecular therapy oncolytics · 2022Review
- Electrochemistry of Cobalta Bis(dicarbollide) Ions Substituted at Carbon Atoms with Hydrophilic Alkylhydroxy and Carboxy Groups.Molecules (Basel, Switzerland) · 2022Article
- Borinostats: solid-phase synthesis of carborane-capped histone deacetylase inhibitors with a tailor-made selectivity profile.Chemical science · 2021Article
- Free three-dimensional carborane carbanions.Chemical science · 2021Article
- Metallacarborane Derivatives Effective againstInternational journal of molecular sciences · 2021Article
- Ruthenacarborane and Quinoline: A Promising Combination for the Treatment of Brain Tumors.Molecules (Basel, Switzerland) · 2021Article
- Preparing (Metalla)carboranes for Nanomedicine.ChemMedChem · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
"There's plenty of room at the bottom" (Richard Feynman, 1959): an invitation for (metalla)carboranes to enter the (new) field of nanomedicine. For two decades, the number of publications on boron cluster compounds designed for potential applications in medicine has been constantly increasing. Hundreds of compounds have been screened in vitro or in vivo for a variety of biological activities (chemotherapeutics, radiotherapeutics, antiviral, etc.), and some have shown rather promising potential for further development. However, until now, no boron cluster compounds have made it to the clinic, and even clinical trials have been very sparse. This review introduces a new perspective in the field of medicinal boron chemistry, namely that boron-based drugs should be regarded as nanomedicine platforms, due to their peculiar self-assembly behaviour in aqueous solutions, and treated as such. Examples for boron-based 12- and 11-vertex clusters and appropriate comparative studies from medicinal (in)organic chemistry and nanomedicine, highlighting similarities, differences and gaps in physicochemical and biological characterisation methods, are provided to encourage medicinal boron chemists to fill in the gaps between chemistry laboratory and real applications in living systems by employing bioanalytical and biophysical methods for characterising and controlling the aggregation behaviour of the clusters in solution.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.